Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Axcella Health Inc (AXLA)

Axcella Health Inc (AXLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Axcella Reports First Quarter Financial Results and Provides Business Update Business Wire - Thu May 4, 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023 Business Wire - Mon Apr 17, 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 0.4009 (-8.89%)
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Business Wire - Thu Mar 30, 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue Business Wire - Wed Feb 15, 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 0.4009 (-8.89%)
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference Business Wire - Thu Feb 9, 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Wall Street - NY Stock Exchange -mHdATQY9fIU-unsplash
Pre-Market Brief: Stocks Mixed As Focus Shifts to Big Tech Earnings Barchart - Tue Jan 24, 2023

March S&P 500 futures (ESH23) are trending down -0.22% this morning after three major U.S. benchmark indices ended the regular session sharply higher as hopes of a less aggressive Federal Reserve boosted...

ESH23 : 3,957.05s (-0.09%)
QCOM : 194.97 (+4.70%)
AMD : 155.87 (+2.83%)
WDC : 73.06 (+4.64%)
CRM : 254.08 (+2.60%)
MSFT : 442.94 (+1.33%)
RHM.D.DX : 493.600 (-0.14%)
AXLA : 0.4009 (-8.89%)
VERB : 0.1020 (-7.27%)
PFLT : 11.38 (-0.18%)
ZION : 49.48 (+1.02%)
PTON : 3.63 (+1.11%)
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue Business Wire - Mon Jan 23, 2023

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions,...

AXLA : 0.4009 (-8.89%)
Axcella Announces Program Reprioritization and Corporate Restructuring Business Wire - Wed Dec 14, 2022

Axcella Therapeutics (Nasdaq: AXLA), a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announces...

AXLA : 0.4009 (-8.89%)
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting Business Wire - Thu Nov 3, 2022

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)
Axcella Reports Third Quarter Financial Results and Provides Business Update Business Wire - Tue Nov 1, 2022

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today...

AXLA : 0.4009 (-8.89%)

Barchart Exclusives

1 Reliable Dividend Stock to Buy at a Discount This July Barchart - Mon Jul 22, 6:30PM CDT
Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot